The differing reimbursement positions highlight how health technology assessment decisions can diverge across UK nations, affecting the timing of patient access to new medicines.

Strong private investment signals renewed confidence in the UK life sciences sector, but public markets remain a challenge.

The MHRA has conditionally approved Novo Nordisk’s GLP-1 therapy for adults with metabolic-associated steatohepatitis, marking another milestone in the evolution of obesity medicines.

Listing of anonymised health data for 500,000 participants highlights growing tension between data access, global research collaboration, and patient trust.